Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Nivolumab (and other agents affecting the anti-programmed death-1 \[anti-PD-1\] pathway) have demonstrated anti-tumor activity in multiple tumor types. Combinations of immune-oncology (IO) agents with complimentary mechanisms as well as radiation represent a promising strategy to improve response rates to immunotherapy and overcome resistance. In this phase I/Ib study, radiation will be used in combination with IO agents nivolumab and anti-IL-8 (BMS-986253) to assess toxicity by organ system and then assess the preliminary efficacy of the treatment regimen. In Part 1, the study will determine

Trial Details

NCT ID
NCT04572451
Phase
PHASE1
Sponsor
Yana Najjar
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • nivolumab
  • BMS-986253
  • Stereotactic Body Radiotherapy (SBRT)
Locations (sample)
  • Chicago, Illinois, United States
  • Pittsburgh, Pennsylvania, United States

Key Eligibility Criteria

  • SAFETY COHORT
  • Patients with advanced/metastatic/unresectable solid tumors progressed on standard therapies. Patients with melanoma and RCC will make up approxima…
  • Patients with 1-4 tumor sites that can be irradiated safely
  • Age \> or equal 18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →